---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-018704"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:40:33.298403+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction

## Summary
- Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).
- Median OS 16.0 months vs. 11.9 months (4.1-month improvement); both dual primary endpoints met.
- NDA under FDA review with PDUFA date of July 11, 2026; MAA under EMA review.
- Relacorilant well-tolerated without increased safety burden; no biomarker selection required.
- Trial enrolled 381 patients across US, Europe, South Korea, Brazil, Argentina, Canada, Australia.

## SEC filing metadata
- accession: 0001193125-26-018704
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/0001193125-26-018704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/d96058d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-018704
- JSON: https://secwatch.observer/filing/0001193125-26-018704.json
- Plain text: https://secwatch.observer/filing/0001193125-26-018704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.